Qingkailing Injection () for Treatment of Children Pneumonia Induced by Respiratory Syncytial Virus: A Meta-Analysis of Randomized Controlled Trials / 中国结合医学杂志

<p><b>OBJECTIVE</b>To evaluate the efficacy and safety of Qingkailing Injection (, QKL) for treatment of children pneumonia caused by respiratory syncytial virus (RSV).</p><p><b>METHODS</b>Randomized clinical trials (RCTs) comparing QKL with ribavirin injection in the treatment of children pneumonia induced by RSV were searched in PubMed, Science Direct, Cochrane Library, Chinese VIP database, CNKI and Wanfang databases from their inception to March 2014. Meta-analyses were performed using RevMan 5.2 software. The methodological quality of the selected RCTs was evaluated by the Modified Jadad Score. The primary outcome measures were effective rate and the secondary outcomes were relief time of fever and cough.</p><p><b>RESULTS</b>Seven RCTs with 992 cases published from 2008 to 2013 were identified. The meta-analysis results indicated that QKL was more effective in cure rate [risk ratios (RR)=1.32, 95% CI (1.17, 1.50), P<0.01], total effective rate [RR=1.07, 95% CI (1.02, 1.13), P=0.009] and less fever clearance time [mean difference=-0.73, 95% CI (-1.22,-0.23), P=0.004], compared with ribavirin injection in the treatment of RSV-induced children pneumonia. No dead case was reported in all trials. There were 3 trials mentioned adverse events, 2 reported no obvious adverse event occurred while 1 reported adverse events described as skin hypersensitivity, elevation of ALT, a mild abnormal of hepatic and renal function in both QKL and ribavirin group.</p><p><b>CONCLUSIONS</b>QKL was an effective and relatively safe option for the treatment of RSV-induced children pneumonia. These therapeutic effects were promising but need to be interpreted with caution due to variations in the treatment and methodological weakness in the studies.</p>

Expression and purification of BDNF-TAT fusion protein in E.coli and its distribution in brain / 中华神经医学杂志

Objective To explore the expression and purification of BDNF-TAT fusion protein in E.coli, and study its brain-targeting and distribution in brain. Methods Plasmid PET-30(a) -BDNF-TAT was transfected into the E.coli BL21 (DE3)pLysS;the expression of PET-30(a)-BDNF-TAT was induced by isopropyl-beta-d-thiogalactopyranoside (IPTG);this BDNF-TAT fusion protein was purified by SP-Sepharose cation exchange column and then renatured by 0.4 mol/L arginine. According to the random number table method, KM mice were divided into 3 groups: BDNF-TAT treatment group (giving 4 μg BDNF-TAT through intravenous injection, n=3), negative control group (giving same volume of saline through intravenous injection, n=3) and blank control group (without giving any treatment, n=3). The whole brain protein was collected 3 h after the injection;Western blotting was used to identify the expression of BDNF-TAT fusion protein;the distributions of BDNF-TAT in the brain tissues were examined by SABC immunohistochemistry. Results BDNF-TAT fusion protein was purified with the purity about 90%. The relative expression of BDNF-TAT fusion protein was 1.897±0.286 in the BDNF-TAT treatment group, 0.615±0.234 in the negative control group, 0.335±0.154 in the blank control group;significant differences between each 2 groups were noted (F=39.019, P=0.000).Western blotting indicated that the content of BDNF-TAT in the mice brain in BDNF-TAT treatment group was obviously higher than that in the negative control group and blank control group (P<0.05);BDNF-TAT fusion protein were widely distributed in CA1,CA3 and DG areas of the hippocampus of brain tissues in the BDNF-TAT treatment group, while no obvious positive staining was noted in the negative control group and blank control group. Conclusion BDNF-TAT fusion protein abundantly expresses in E.coli in the form of inclusion bodies, and can target the brain tissue via a systemic route.